Billionaire investor Ron Baron has a message for those who are trying to predict how day-to-day news will impact the stock market: Stop. (more…)
Reese: Rate Hike Reality Far More Complex Than It Appears
If you’ve been listening to the financial media in recent months, you’ve probably gotten the idea that the interest rate hikes that seem to be on the horizon spell big-time…
Bill Nygren On ... Everything
GuruFocus’s two-part interview with top fund manager Bill Nygren is a must-read, offering insights into Nygren’s incredibly successful value approach. (more…)
Fisher On Why Hillary Won't Win In 2016 -- And What That Means For Stocks
While many believe it’s a foregone conclusion that Hillary Clinton will win the 2016 presidential election, top strategist Kenneth Fisher says history shows otherwise –and that, he says, is likely…
Fisher On Why Hillary Won't Win In 2016 -- And What That Means For Stocks
While many believe it’s a foregone conclusion that Hillary Clinton will win the 2016 presidential election, top strategist Kenneth Fisher says history shows otherwise –and that, he says, is likely…
Sonders, Schwab: Let's Get Normalized
A closely fought “tug-of-war” between bulls and bears has kept stocks trading in a tight range this year, and Charles Schwab strategists think the battle could continue for a while…
Sonders, Schwab: Let's Get Normalized
A closely fought “tug-of-war” between bulls and bears has kept stocks trading in a tight range this year, and Charles Schwab strategists think the battle could continue for a while…
Gross On The Next Liquidity Crisis
Bond guru Bill Gross says that, once the global flood of quantitative easing ends, we could be in for another liquidity crisis. (more…)
Cooperman: Rate Hike Fixation Lacking In Reason
Top value strategist Leon Cooperman says that, while stocks are not cheap, the factors that would cause a bear market are “just not present” right now. (more…)
Klarman's Biotech Bent
Has star value manager Seth Klarman found the secret to investing successfully in the growth-crazed biotech industry? Andrew Feinberg says the answer is a “qualified yes.” (more…)